Abrégé

The present invention relates to a device for filtering fluid samples and a method for detecting concentration of particles, and more particularly to a filtering device capable of filtering fluid samples at different filtering levels and a method for detecting the concentration of particles trapped in the filters of the device for each fluid sample.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• B01D 63/08 - Modules à membranes planes

Abrégé

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer

Abrégé

The present invention provides anti-Siglec-15 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-15 antibodies and fragments thereof.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating a ketone (—C═O) or an oxime group (—C═N—O—) as position C3 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

Classes IPC  ?

• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
• A61K 39/08 - Clostridium, p. ex. Clostridium tetani
• A61K 39/095 - Neisseria
• A61K 39/13 - Virus de la poliomyélite
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61P 35/00 - Agents anticancéreux
• C07H 23/00 - Composés contenant du bore, du silicium ou un métal, p. ex. chélates ou vitamine B12

Abrégé

The present invention relates to a novel RNA-guided Cas nuclease having the sequence shown in SEQ. ID. No.1 and designated α-synCs. It shares low sequence homology with known Cas nucleases and has the following advantageous properties: (i) ability to target for nucleolytic cleavage all of dsDNA, ssDNA and ssRNA (ii) able to non-sequence-specifically trans-cleave all of dsDNA, ssDNA and ssRNA regardless of which target it has been activated by (ii) appears to have no PAM specificity (iii) ability to use a wide range of crRNAs belonging to a plurality of Cas nucleases for targeted cleavage and (iv) ability to process pre-crRNA transcripts.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• A61K 38/46 - Hydrolases (3)
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

Classes IPC  ?

• C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
• C07K 14/445 - Plasmodium
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The invention relates to an agent binding specifically to the sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 wherein said agent is an immunoglobulin agent or a non-immunoglobulin agent selected from the group consisting of a peptide aptamer, a nucleic acid aptamer, a DARPin, an affibody, and an anticalin. The invention also relates to a nucleic acid, an expression cassette, a vector, a cell and a nanoparticle comprising the agent of the invention. The invention also relates to a pharmaceutical composition and to its use in preventing and/or treating cancer, metastasis or fibrosis. The invention also relates to a method for screening compounds capable of inhibiting Wnt-11.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61P 35/00 - Agents anticancéreux
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 14/475 - Facteurs de croissanceRégulateurs de croissance

Abrégé

The present invention relates to an oral composition of ciclopirox or a derivate thereof which do not exhibit gastrointestinal toxicity and comprises a therapeutically effective amount of ciclopirox, tocopherol and alginate or their derivates.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

Abrégé

The present invention relates to methods for the purification by affinity binding of SUMO (Small-ubiquitin modifier) and SUMO-conjugate proteins by the use of fusion proteins comprising tandem arrangements of high affinity SUMO interacting motifs.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand

Abrégé

The present application relates to compounds based on a triterpene glycoside saponin scaffold, which bear an acyl chain comprising a photoreactive moiety and a terminal biotin, of general formula (I). The present application also relates to the use of said compounds and compositions thereof in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers as well as its use as chemical probe in photoaffinity labeling (PAL) (for photocrosslinking with interacting partners) followed by affinity purification of the covalent complex and MS-based proteomics for target identification and elucidation of the protein receptor.

Classes IPC  ?

• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• C07H 1/08 - SéparationPurification à partir de produits naturels
• C07H 15/256 - Radicaux polyterpène
• C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes

Abrégé

The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The present invention relates to the use of uroporphyrin I (UROI) or a pharmaceutically acceptable salt or metallo-complex thereof for the treatment and/or prevention of transmissible spongiform encephalopathies (TSE) or prion diseases.

Classes IPC  ?

• A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention relates to a method for diagnosing liver disease in a subject and/or for triaging a subject for liver disease, which is based on the detection of the expression level of GNMT in a urine sample from said subject. The invention also relates to methods for monitoring progression of liver disease, for monitoring a patient's response to a therapy for liver disease, and for selecting a subject to be treated for liver disease. The invention also describes the use of reagents specific for determining the expression level of GNMT in a urine sample from a subject, for in vitro diagnosing a liver disease in said subject.

Classes IPC  ?

• G01N 33/576 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour l'hépatite
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Produits et services

Enzymes for industrial purposes; Enzymes for scientific purposes; Enzyme preparations for industrial purposes; Enzyme preparations for scientific purposes; Enzymes for genome editing for scientific and research purposes; Enzymes preparations for genome editing for scientific and research purposes; Diagnostic preparations, other than for medical or veterinary purposes; Reagents for scientific purposes; Reagents for research purposes; Reagents for genome editing for scientific and research purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr controls being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr reagents for genome editing for scientific and research purposes; Chemical substances for use in the biotechnological industry; Chemical reagents for use in biotechnology, other than for medical or veterinary use; Chemical preparations for use in DNA analysis, other than medical use; Enzyme preparations for use in DNA analysis, other than medical use; Enzymes for use in DNA analysis, other than medical use; Chemical preparations for use in RNA analysis, other than medical use; Enzyme preparations for use in RNA analysis, other than medical use; Enzymes for use in RNA analysis, other than medical use; Enzymes for editing genomes for medical or veterinary research purposes Enzymes for medical purposes; Enzymes for veterinary purposes; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Enzyme preparations for editing genomes for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for genome editing for medical or veterinary purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr controls being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr reagents for genome editing for medical or veterinary purposes; Chemical preparations for use in DNA analysis for medical or veterinary purposes; Enzyme preparations for use in DNA analysis for medical or veterinary purposes; Enzymes for use in DNA analysis for medical or veterinary purposes; Chemical preparations for use in RNA analysis for medical or veterinary purposes; Enzyme preparations for use in RNA analysis for medical or veterinary purposes; Enzymes for use in RNA analysis for medical or veterinary purposes Research in the field of gene therapy; Advisory services relating to gene therapy research; Research in the field of gene editing technology; Advisory services in the field of gene editing technology; Genome editing for scientific purposes; Genome editing for scientific research purposes; Genome editing for industrial purposes; Genome editing for use in biotechnology, other than for medical or veterinary use Genome editing for medical purposes; Genome editing for veterinary purposes

Abrégé

T. thermosaccharolyticumThermomyces lanuginosus,Thermomyces lanuginosus, obtaining a novel acylated derivate of phloretin, particularly the phloretin 4'-O-(6-O- lauroyl)-α-D-glucopyranoside. Further, the present invention relates the use of phloretin 4'-O-(6-O-lauroyl)-α-D-glucopyranoside as antioxidant.

Classes IPC  ?

• C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
• A61P 17/18 - Antioxydants, p. ex. antiradicaux
• C12P 7/6454 - Glycérides par estérification
• C12P 19/02 - Monosaccharides

Produits et services

Enzymes for industrial purposes; Enzymes for scientific purposes; Enzyme preparations for industrial purposes; Enzyme preparations for scientific purposes; Enzymes for genome editing for scientific and research purposes; Enzymes preparations for genome editing for scientific and research purposes; Diagnostic preparations, other than for medical or veterinary purposes; Reagents for scientific purposes; Reagents for research purposes; Reagents for genome editing for scientific and research purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr controls being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr reagents for genome editing for scientific and research purposes; Chemical substances for use in the biotechnological industry; Chemical reagents for use in biotechnology, other than for medical or veterinary use; Chemical preparations for use in DNA analysis [other than medical]; Enzyme preparations for use in DNA analysis [other than medical]; Enzymes for use in DNA analysis [other than medical]; Chemical preparations for use in RNA analysis [other than medical]; Enzyme preparations for use in RNA analysis [other than medical]; Enzymes for use in RNA analysis [other than medical]. Enzymes for medical purposes; Enzymes for veterinary purposes; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Enzymes for editing genomes for medical or veterinary research purposes; Enzyme preparations for editing genomes for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for genome editing for medical or veterinary purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr controls being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr reagents for genome editing for medical or veterinary purposes; Chemical preparations for use in DNA analysis for medical or veterinary purposes; Enzyme preparations for use in DNA analysis for medical or veterinary purposes; Enzymes for use in DNA analysis for medical or veterinary purposes; Chemical preparations for use in RNA analysis for medical or veterinary purposes; Enzyme preparations for use in RNA analysis for medical or veterinary purposes; Enzymes for use in RNA analysis for medical or veterinary purposes. Research in the field of gene therapy; Advisory services relating to gene therapy research; Research in the field of gene editing technology; Advisory services in the field of gene editing technology; Genome editing for scientific purposes; Genome editing for scientific research purposes; Genome editing for industrial purposes; Genome editing for use in biotechnology, other than for medical or veterinary use. Genome editing for medical purposes; Genome editing for veterinary purposes.

Abrégé

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating a ketone (-C=O) or an oxime group (-C=N-O-) as position C3 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

Classes IPC  ?

• C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
• C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
• C07K 14/445 - Plasmodium
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61K 47/02 - Composés inorganiques
• A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
• A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to an oral composition of ciclopirox or a derivate thereof which do not exhibit gastrointestinal toxicity and comprises a therapeutically effective amount of ciclopirox, tocopherol and alginate or their derivates.

Classes IPC  ?

• A61K 9/08 - Solutions
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

Classes IPC  ?

• A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07H 15/256 - Radicaux polyterpène
• C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
• C07K 14/445 - Plasmodium
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a method for expanding a population of T-lymphocytes, to the population of expanded T-lymphocytes obtained by this method and to the medical use of this population of expanded T-lymphocytes for the treatment of cancer or of an infectious disease.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The present invention relates to a method for diagnosing inflammation in a subject based on determining the level of expression of IRF4 in sample from said subject and to a method for designing a personalized therapy in a subject suffering from inflammation. The invention also relates to a combination comprising a compound suitable for treating inflammation and a compound selected from the group consisting of a glycolysis inhibitor, an IRF4 mimetic, a Ras inhibitor, a PI-3K inhibitor, a mTOR inhibitor, a STAT3 inhibitor, an antioxidant and combinations thereof and to medical uses for preventing and/or treating inflammation. The invention also relates to the use of a kit comprising a reagent suitable for determining the level of expression of IRF4 in a sample for diagnosing inflammation in a subject.

Classes IPC  ?

• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries

Abrégé

The present invention relates to a CNNM4 inhibitor for use in the treatment of an acute or a chronic liver, kidney and/or lung disease in a subject, and to pharmaceutical compositions comprising a therapeutically effective amount of a CNNM4 inhibitor and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for diagnosing a liver disease, a kidney disease or a lung disease in a subject, and to in vitro methods for identifying a compound potentially useful for reducing an induced CNNM4-mediated disease or condition in a cell.

Classes IPC  ?

• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
• A61P 3/06 - Antihyperlipémiants
• A61P 3/12 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins

Abrégé

The present invention relates to new methods for predicting the outcome of in vitro fertilization (IVF) procedures, as well as selecting the subjects to undergo IVF treatments. It also relates to methods for selecting IVF treatments and decision-making in said treatments as well as wash solutions for use in the treatment of infertility.

Classes IPC  ?

• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

The present invention relates to methods useful for predicting the outcome of a patient suffering from prostate cancer or for predicting the response to therapy of a patient suffering from prostate cancer, which comprise determining, in a sample from the patient, the ratio between the average expression levels of a first gene signature and the average expression levels of a second gene signature, wherein the first gene signature is selected from the group consisting of HI1 (i.e., the CPOX, GAL3St4, ORAI2 and NIPA1 genes) and HI2 (i.e., the KHK, NOX4, PTGES3 and RRM2 genes); wherein the second gene signature is selected from the group consisting of LO1 (i.e., the ATP8B1, CDO1, CHRNA2, GLB1L3, GNE, KATNAL2, PTGIS, SLC6A14, TP53INP2, and TRIM47 genes), LO2 (i.e., the ASPA, CDO1, CYP3A5, GLB1L2, GNE, ITPKC, KCTD14, PAH, PHYHD1, SIRT1, SLC40A1, SLC7A4, and SRD5A genes) and LO3 (i.e., the ASPA, CDO1, GFPT2, GNE, ITPKC, PAH, SIRT1 and TPMT genes). These methods can be used to identify those patients who harbour an indolent/ low risk prostate cancer, or those that are at a high risk of recurrence or metastasis. The identification of these subgroups of patients may guide the selection of therapies, improving financial and health outcomes. Moreover, the expression levels of these genes can also be used for the selection of a patient to be treated for low risk, indolent, localised, advanced, recurrent or metastatic prostate cancer. Further, the invention also relates to kits and reagents to determine the expression levels of these genes.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention is directed to a device for containing and placing ticks or other small sized animals on laboratory animals in order to perform controlled feeding experiments and a method of use thereof; in particular the present invention proposes a capsule (10) that is compact in size and easily accessible to permit feeding of small sized animals such as ticks on laboratory and larger animals.

Classes IPC  ?

• A01K 1/03 - Logements pour animaux domestiques ou de laboratoire
• A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés

Abrégé

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.

Classes IPC  ?

• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/06 - OnguentsExcipients pour ceux-ci

Abrégé

The present invention relates to a CNNM4 inhibitor for use in the treatment of an acute or a chronic liver, kidney and/or lung disease in a subject, and to pharmaceutical compositions comprising a therapeutically effective amount of a CNNM4 inhibitor and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for diagnosing a liver disease, a kidney disease or a lung disease in a subject, and to in vitro methods for identifying a compound potentially useful for reducing an induced CNNM4-mediated disease or condition in a cell.

Classes IPC  ?

• A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles

Produits et services

Computer software; Electronic publications, downloadable; all the aforementioned related to biosciences. Printed publications; Printed matter; Books; Magazines [periodicals]; Instructional and teaching material (except apparatus); Stationery; all the aforementioned related to biosciences. Education; Providing of training; Organisation of conferences, exhibitions and competitions; Audio, video and multimedia production, and photography; Library services; Publishing and reporting; all the aforementioned related to biosciences. Science and technology services; Research relating to technology; Scientific services and design relating thereto; Technological services and design relating thereto; Scientific research; Biological research; Biological analysis; Biology consultancy; Medical and pharmacological research services; Biological big data analytics; Software design and development; Design and development of computer hardware; Testing, authentication and quality control; Scientific testing services; Software as a service [SaaS]; Providing temporary use of non-downloadable software applications accessible via a web site; all the aforementioned related to biosciences. Medical testing for diagnostic or treatment purposes; Drug screening for medical purposes; Performing diagnosis of diseases; all the aforementioned related to biosciences.

Produits et services

Computer software; Electronic publications, downloadable. Education; Providing of training; Organisation of conferences, exhibitions and competitions; Audio, video and multimedia production, and photography; Library services; Publishing and reporting. Science and technology services; Research relating to technology; Scientific services and design relating thereto; Technological services and design relating thereto; Scientific research; Biological research; Biological analysis; Biology consultancy; Medical and pharmacological research services; Biological big data analytics; Software design and development; Design and development of computer hardware; Testing, authentication and quality control; Scientific testing services; Software as a service [SaaS]; Providing temporary use of non-downloadable software applications accessible via a web site. Medical services; Medical treatment services; Medical testing for diagnostic or treatment purposes; Preparation of prescriptions by pharmacists; Drug screening for medical purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Performing diagnosis of diseases.

Abrégé

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP).

Classes IPC  ?

• A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme

Abrégé

Methods and compounds useful to treat drug-induced diseases and conditions are provided. Methods of administering one or more MCJ-inhibiting compounds to decrease MCJ polypeptide activity in cells, tissues, and/or subjects as a treatment for a drug-induced disease or condition are provided.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Abrégé

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.

Classes IPC  ?

• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention relates to biomarkers for colorectal cancer. Specifically, it relates to metabolic markers as a screening, diagnostic or monitoring tool for detecting colorectal cancer (CRC) and /or advanced adenoma (AD) in a subject. In a particular embodiment, it refers to an in vitro method for the screening, diagnosis or monitoring of colorectal cancer and /or advanced adenoma in a subject, said method comprising the following steps: a) determining the levels of the metabolic marker ChoE(18:2) in a feces sample isolated from said subject; b) comparing the levels in said feces sample with a reference value; wherein an increase of ChoE(18:2) levels in the subject sample with regard to said reference value is indicative of CRCand /or AD.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

Methods and compounds useful to treat diseases and conditions are provided. Methods of administering one or more microRNA-inhibitor compounds or one or more microRNA-enhancing compounds to cells, tissues, and/or subjects as a treatment for a disease or condition are provided.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a set of markers, preferably proteins, all associated with the path of the system for activating the complement, which are particularly useful for predicting and/or forecasting the compatibility in vitro of a biomaterial, for example such as prosthetic joints, dental prostheses, valves, stents, etc. in the patient. In addition, the present invention comprises an in vitro method for predicting and/or forecasting the compatibility of said materials by determining the peptide profile described in the invention, as well as a kit and/or a device for carrying out said method.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP).

Classes IPC  ?

• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention relates to methods useful for predicting the outcome of a patient suffering from prostate cancer or for predicting the response to therapy of a patient suffering from prostate cancer, which comprise the determination of the expression level of PGC1A or of a gene signature under the control of PGC1A. These methods can be used to identify those patients who are at a high risk of recurrence or metastasis. The identification of this subgroup of patients may guide the selection of therapies, improving financial and health outcomes. Moreover, the expression levels of these genes can also be used for the selection of a patient to be treated for advanced, recurrent or metastatic prostate cancer. Further, the invention also relates to kits and reagents to determine the expression levels of these genes.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

Methods and compounds useful to treat diseases and conditions are provided. Methods of administering one or more microRNA-inhibitor compounds or one or more microRNA-enhancing compounds to cells, tissues, and/or subjects as a treatment for a disease or condition are provided.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose

Abrégé

Methods and compounds useful to treat drug-induced diseases and conditions are provided. Methods of administering one or more MCJ-inhibiting compounds to decrease MCJ polypeptide activity in cells, tissues, and/or subjects as a treatment for a drug-induced disease or condition are provided.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes

Abrégé

4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).

Classes IPC  ?

• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
• A61K 31/404 - Indoles, p. ex. pindolol
• A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine

Abrégé

The potential use of these "SUMO receptors" to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The invention relates to methods for the diagnosis of liver damage. The method relies on the determination of certain metabolic markers in a biological sample of the subject which are up- or down-regulated in injured liver.

Classes IPC  ?

• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

A device for storing a plurality of cryo-grid storage boxes in a dewar, comprising a substantially cylindrical body having a diameter, wherein said diameter is such that the device fits substantially exactly in a dewar canister, and said cylindrical body comprises a plurality of storage holes, the cross-sectional dimensions of the storage holes being adapted to a standard-size cryo-grid storage box such that each storage hole fits at least one standard-size cryo-grid storage box.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
• B01L 9/06 - Supports de tubes à essaiPorte-tubes à essai
• F25D 25/00 - Introduction, port ou déchargement des produits à refroidir
• A61N 1/02 - ÉlectrothérapieCircuits à cet effet Parties constitutives